Radiopharm Theranostics Limited (RADX)
NASDAQ: RADX · Real-Time Price · USD
4.660
-0.010 (-0.21%)
At close: Apr 10, 2026, 4:00 PM EDT
4.300
-0.360 (-7.73%)
After-hours: Apr 10, 2026, 7:18 PM EDT
Radiopharm Theranostics Revenue
Radiopharm Theranostics had revenue of 6.20M AUD in the half year ending December 31, 2025, with 52.60% growth. This brings the company's revenue in the last twelve months to 16.28M, up 4,823.49% year-over-year. In the fiscal year ending June 30, 2025, Radiopharm Theranostics had annual revenue of 12.51M with 538.86% growth.
Revenue (ttm)
16.28M AUD
Revenue Growth
+4,823.49%
P/S Ratio
5.09
Revenue / Employee
1,162,745 AUD
Employees
14
Market Cap
55.26M USD
Revenue Chart
* This company reports financials in AUD.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Jun 30, 2025 | 12.51M | 10.55M | 538.86% |
| Jun 30, 2024 | 1.96M | -4.25M | -68.46% |
| Jun 30, 2023 | 6.21M | - | - |
| Jun 30, 2022 | - | - | - |
| Jun 30, 2021 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Xilio Therapeutics | 43.77M |
| Metagenomi Therapeutics | 25.21M |
| Aligos Therapeutics | 2.19M |
| ImageneBio | 800.00K |
| Mereo BioPharma Group | 500.00K |
RADX News
- 3 days ago - Radiopharm Theranostics and Siemens Healthineers Sign Clinical Supply Agreement for RAD101 in the U.S. - GlobeNewsWire
- 14 days ago - Radiopharm Theranostics Doses First Patient in Phase 1 Clinical Study of RAD 402 in Advanced Prostate Cancer - GlobeNewsWire
- 17 days ago - Radiopharm Theranostics Eyes Pivotal Trial Path After Encouraging Interim Results - Benzinga
- 2 months ago - Radiopharm Theranostics Reports Half-Year Financial Results and Business Updates - GlobeNewsWire
- 3 months ago - RAD Increases Ownership in Radiopharm Ventures to 87.5% - GlobeNewsWire
- 4 months ago - Why Is Radiopharm Theranostics Stock Rallying Over 140%? - Benzinga
- 4 months ago - Radiopharm Theranostics Achieves Primary Endpoint in 92% of Patients at Interim Analysis of RAD 101 Phase 2b Imaging Trial in Brain Metastases - GlobeNewsWire
- 4 months ago - Radiopharm Theranostics (RADX): Analyst Maintains 'Buy' as Price Target Adjusts | RADX Stock News - GuruFocus